Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 57 of 73 for:    HYDROCHLOROTHIAZIDE AND LOSARTAN

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02521233
Recruitment Status : Withdrawn (Sponsor decision)
First Posted : August 13, 2015
Last Update Posted : January 19, 2017
Sponsor:
Information provided by (Responsible Party):
EMS

Brief Summary:
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Condition or disease Intervention/treatment Phase
Essential Arterial Hypertension Drug: Candesartan + Chlorthalidone (8mg+12,5mg) Drug: Candesartan + Chlorthalidone (8 mg + 25 mg) Drug: losartan+hydrochlorothiazide Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety Evaluation of the New Association on Fixed Dose of Candesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control
Study Start Date : November 2016
Estimated Primary Completion Date : May 2017
Estimated Study Completion Date : August 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Test 1: Candesartan + Chlorthalidone
The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 12,5 mg) a day, in the morning.
Drug: Candesartan + Chlorthalidone (8mg+12,5mg)
Other Name: Candesartan + Chlorthalidone

Experimental: Test 2: Candesartan + Chlorthalidone
The patients will take 1 tablet (Candesartan cilexetil 8 mg + Chlorthalidone 25 mg) a day, in the morning.
Drug: Candesartan + Chlorthalidone (8 mg + 25 mg)
Other Name: Candesartan + Chlorthalidone

Active Comparator: Comparator: losartan+hydrochlorothiazide (Hyzaar®)
he patients will take 1 tablet (Losartan 50 mg + Hydrochlorothiazide 12,5 mg) a day, in the morning.
Drug: losartan+hydrochlorothiazide
Other Name: Hyzaar ®




Primary Outcome Measures :
  1. Efficacy of essential hypertension control based on proportion of participants who achieve the therapeutic goal [ Time Frame: 60 days ]

Secondary Outcome Measures :
  1. Safety will be evaluated by the occurrences of adverse events. [ Time Frame: 9 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed Consent of the patient;
  • Participants with decompensated essential hypertension, classified into stage 1 (with high or very high cardiovascular risk), stage 2 or stage 3 according to the Brazilian Society of Cardiology (2010), who have never been treated and have indication for drug combination treatment.

Obs: The diagnosis may be established by previous evaluation of two blood pressure measures ≥ 140/90 mmHg, with two months difference between measurements

Exclusion Criteria:

  • Patients with any clinically significant disease that in the investigator is opinion can not participate in the study;
  • Secondary hypertension diagnosis or blood pressure above 190x100 mmHg in the screening/randomization visit;
  • Morbid obesity or immunocompromised patients;
  • Participants with greater than 10 mmHg difference in the measurements of systolic or diastolic blood pressure between the two arms;
  • Participants who do not have the two upper limbs;
  • Participants with important electrocardiographic changes;
  • Creatinine clearance - less than 60 mL /min;
  • History of hypertensive emergencies and cardiovascular and / or moderate to severe cerebrovascular events in the past 6 months;
  • Microalbuminuria in urine sample greater than 30 mg/g;
  • Patients with history of hypersensitivity to any of the formula compounds;
  • Pregnancy or risk of pregnancy and lactating patients;
  • Participation in clinical trial in the year prior to this study.

Layout table for additonal information
Responsible Party: EMS
ClinicalTrials.gov Identifier: NCT02521233     History of Changes
Other Study ID Numbers: CACEMS0514OR-III
First Posted: August 13, 2015    Key Record Dates
Last Update Posted: January 19, 2017
Last Verified: January 2017
Additional relevant MeSH terms:
Layout table for MeSH terms
Losartan
Hydrochlorothiazide
Hypertension
Vascular Diseases
Cardiovascular Diseases
Candesartan
Candesartan cilexetil
Chlorthalidone
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Sodium Chloride Symporter Inhibitors
Membrane Transport Modulators